title: GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting.
abstract: Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by the association of arthritis and periarticular inflammation in patients with psoriasis. In addition to a heterogeneous and variable clinical course, PsA is complex and multifaceted and may include prominent involvement in the peripheral and axial diarthrodial joints, the skin and nails, and in periarticular structures such as entheses. A central mission of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is to develop guidelines, based upon the best scientific evidence, for the optimal treatment of patients with PsA. Guidelines were previously published in 2009 based on an evidence-based systematic review. Given important recent developments and robust ongoing research into the treatment of PsA, GRAPPA undertook to update the guidelines. Herein we outline the specific methods and procedures used both in the initial and the current evidence-based, systematic reviews of treatments for PsA. We also review the numerous discussions regarding how best to finalize and publish these new guidelines in 2014.
authors.affiliation: From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York; and the University of California at San Diego, California, USA.L.C. Coates, MRCP, PhD, UK National Institute for Health Research Clinical Lecturer, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center; A.F. Kavanaugh, MD, Professor of Medicine, University of California at San Diego. L.C.Coates@leeds.ac.uk.
authors.forename: Laura C
authors.initials: LC
authors.lastname: Coates
authors.affiliation: From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York; and the University of California at San Diego, California, USA.L.C. Coates, MRCP, PhD, UK National Institute for Health Research Clinical Lecturer, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center; A.F. Kavanaugh, MD, Professor of Medicine, University of California at San Diego.
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Ritchlin
authors.affiliation: From the Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York; and the University of California at San Diego, California, USA.L.C. Coates, MRCP, PhD, UK National Institute for Health Research Clinical Lecturer, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center; A.F. Kavanaugh, MD, Professor of Medicine, University of California at San Diego.
authors.forename: Arthur F
authors.initials: AF
authors.lastname: Kavanaugh
mesh_terms: D015535:Arthritis, Psoriatic / Q000628:therapy*; D035843:Biomedical Research; D019317:Evidence-Based Medicine; D006126:Group Processes; D006801:Humans; D017410:Practice Guidelines as Topic; D012720:Severity of Illness Index
keywords: BIOLOGICS; DACTYLITIS; ENTHESITIS; PSORIASIS; PSORIATIC ARTHRITIS; TREATMENT